A third-party manufacturing facility has apparently been flagged by the FDA. The plant is owned by pharmaceutical industry peer Novo Nordisk. 10 stocks we like better than Scholar Rock › A potential ...

Although there are many examples throughout history of positive changes in top company management teams, important personnel moves tend to unsettle investors. They get worried that significant changes ...

Shares of Scholar Rock (SRRK) soared 16% on Wednesday after the company announced that its investigational drug Apitegromab, in combination with Tirzepatide, helped preserve lean mass during ...

Well before market open, Leerink Partners' Mani Foroohar launched his coverage of Scholar Rock, rating the healthcare stock as an outperform (i.e., buy) at a price target of $51 per share. That ...

In the RESILIENT SMA study, taldefgrobep showed clinically meaningful improvements in motor function at all time points on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did ...

The company posted a relatively steep bottom-line shortfall in its second quarter. This was tempered by a business update that featured more positive news. Scholar Rock's second quarter saw the ...

New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore Capital LP’s ...